AKUMS
FAIRLY_VALUEDAkums Drugs and Pharmaceuticals Limited
Pharma · NSE
↓ 2.8% vs fair value
52W Low
₹405
+22.1% from low
52W High
₹623
-20.6% from high
Valuation Gauge
Current Price
₹495
Fair Value
₹481
Fair Value Analysis
₹481
Based on earnings growth potential for Pharma sector companies | CAUTION: ROCE declining (latest 14.8%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 11.8% (ROE 10.3%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 10.3% is acceptable for Pharma sector (benchmark: 18%)
Debt & Leverage
D/E ratio of 0.0x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 24.6x trades at a 42% discount to Pharma sector median (42x) — attractively valued
Cash Flow
FCF margin of 4.7% — thin cash generation, watch capex trends
Earnings Growth
5yr EPS CAGR of 18.2% is in line with the Pharma sector average of 15.3%
Dividend
No dividend — typical for growth-stage companies
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-1.0%
Free cash flow / market cap
Revenue Growth (YoY)
+14.8%
Year-on-year revenue change
Profit Growth (YoY)
+3.0%
Year-on-year PAT change
Operating Cash Flow
₹465 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹20.2
P/E Ratio
24.6x
P/B Ratio
2.6x
ROE
10.4%
ROCE
11.7%
Debt / Equity
0.03x
Beta
—
Div Yield
—
FCF (Cr)
₹193 Cr
Revenue (Cr)
₹4,071 Cr
EPS Growth 5Y
—
Mkt Cap (Cr)
₹7,646 Cr
52W High
₹623
52W Low
₹405
Book Value/Share
₹195
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹4.3K Cr | ₹464 Cr | 11.0% | ₹325 Cr | ₹20.21 |
| 2025-03-31 | ₹4.1K Cr | ₹465 Cr | 11.0% | ₹344 Cr | ₹21.49 |
| 2024-03-31 | ₹4.2K Cr | ₹123 Cr | 3.0% | ₹1 Cr | ₹-0.28 |
| 2023-03-31 | ₹3.7K Cr | ₹294 Cr | 8.0% | ₹98 Cr | ₹6.63 |
| 2022-03-31 | ₹3.7K Cr | ₹-89 Cr | -2.0% | ₹-251 Cr | ₹-35.30 |
| 2021-03-31 | ₹2.7K Cr | ₹237 Cr | 9.0% | ₹123 Cr | ₹949.10 |
| 2020-03-31 | ₹2.4K Cr | ₹174 Cr | 7.0% | ₹44 Cr | ₹335.61 |
| 2016-03-31 | ₹1.7K Cr | ₹144 Cr | 9.0% | ₹61 Cr | ₹523.23 |
| 2015-03-31 | ₹1.5K Cr | ₹124 Cr | 8.0% | ₹43 Cr | ₹366.55 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant